Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Qingdao Baheal Medical Inc. (301015.SZ)
CNY23.94
+0.84 (+3.64%)
CN SHZ Healthcare Drug Manufacturers - General
Address
No. 88 Kaifeng Road 250000
Qingdao, CN
Qingdao, CN
CEO
Gang Fu
Website
bahealpharma.com
IPO
2021-06-30
ISIN CNE100004LR8
Description
Qingdao Baheal Medical Inc., established in 2005 and headquartered in Qingdao, China, operates as a pharmaceutical company. The firm's activities encompass the entire spectrum of drug development, from initial research to manufacturing and sales of various medicinal products. A key offering in its portfolio is vitamin D calcium in chewable tablet form.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY23.94
+0.84 (+3.64%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
9M
Beta
0.41
Float Shares
452.36M
Free Float %
86.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.54% | -1.97% | -9.21% | -5.93% | +0.27% | -5.17% | +25.03% | -20.86% | -60.15% | -60.15% | -60.15% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
23.94
DCF (Unlevered)
31.19
+30.3%
DCF (Levered)
56.32
+135.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.00
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%-7.3% Q1'26: -3.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%-30.5% Q1'26: +43.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+9.9% Q1'26: -1.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+11.0% Q1'26: +12.4% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+18.0% ★ Q1'26: +18.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%-1.3% ★ Q1'26: +1.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×3.48× Q1'26: 4.21× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.91B
est.
|
7.51B
est: 7.84B (-4.2%)
|
7.05B
est: 7.84B (-10.1%)
|
8.26B
est: 7.80B (+5.8%)
|
8.09B
est: 7.92B (+2.3%)
|
7.51B
est: 7.97B (-5.9%)
|
8.03B
7.89B – 8.16B
+0.7% YoY
|
8.59B
7.86B – 9.44B
+7.0% YoY
|
7.99B
7.57B – 8.47B
-7.0% YoY
|
| EBITDA |
829.52M
est.
|
754.24M
est: 822.05M (-8.2%)
|
653.25M
est: 822.05M (-20.5%)
|
1.15B
est: 818.01M (+40.5%)
|
1.10B
est: 1.38B (-20.5%)
|
945.69M
est: 1.39B (-32.2%)
|
1.40B
1.38B – 1.43B
+0.7% YoY
|
1.50B
1.37B – 1.65B
+7.0% YoY
|
1.40B
1.32B – 1.48B
-7.0% YoY
|
| EBIT |
793.33M
est.
|
730.91M
est: 786.19M (-7.0%)
|
631.40M
est: 786.19M (-19.7%)
|
1.09B
est: 782.33M (+39.6%)
|
1.05B
est: 1.15B (-9.2%)
|
826.63M
est: 1.16B (-28.9%)
|
1.17B
1.15B – 1.19B
+0.7% YoY
|
1.25B
1.15B – 1.38B
+7.0% YoY
|
1.17B
1.10B – 1.24B
-7.0% YoY
|
| Net Income |
426.84M
est.
|
502.09M
est: 513.29M (-2.2%)
|
421.64M
est: 513.29M (-17.9%)
|
712.06M
est: 672.68M (+5.9%)
|
691.59M
est: 858.70M (-19.5%)
|
474.69M
est: 589.36M (-19.5%)
|
690.69M
643.43M – 744.46M
+17.2% YoY
|
768.03M
544.23M – 991.83M
+11.2% YoY
|
720.03M
670.76M – 776.07M
-6.3% YoY
|
| SGA |
1.46B
est.
|
1.32B
est: 1.45B (-9.0%)
|
1.13B
est: 1.45B (-22.0%)
|
1.59B
est: 1.44B (+10.7%)
|
1.80B
est: 1.47B (+22.6%)
|
1.32B
est: 1.48B (-11.0%)
|
1.49B
1.46B – 1.51B
+0.7% YoY
|
1.59B
1.46B – 1.75B
+7.0% YoY
|
1.48B
1.40B – 1.57B
-7.0% YoY
|
| EPS |
0.79
est.
|
0.96
est: 0.95 (+1.1%)
|
0.85
est: 0.95 (-10.5%)
|
1.36
est: 1.25 (+9.2%)
|
1.32
est: 1.61 (-18.0%)
|
0.90
est: 1.11 (-18.6%)
|
1.30
1.21 – 1.40
+17.2% YoY
|
1.44
1.02 – 1.86
+11.2% YoY
|
1.35
1.26 – 1.46
-6.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 5/5 | 5/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
476.55M
OE per share TTM
0.89
Owner's Yield
4.12%
Maintenance CapEx ratio
40.31%
Maint CapEx / Avg PPE
6.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 15 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 105.4K | 0.65% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 341.3K | 0.06% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 24.9K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 11.1K | 0.48% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.23M | 0.06% |
| 6 | Vanguard ESG International Stock ETF VSGX | 0.00% | 14.7K | 0.10% |
| 7 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.34M | 0.05% |
| 8 | Vanguard Total World Stock ETF VT | 0.00% | 120.9K | 0.06% |
| 9 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 2.0K | 0.22% |
| 10 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 6.0K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
269.8K
Shares Outstanding
525.62M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bi Quan Wang | Deputy General Manager | — | female |
| Feng Liu | Accounting Supervisor | — | — |
| Gang Fu | Chairman & GM | — | male |
| Ting Wei Wang | Deputy General Manager | — | male |
| Xiaowei Zhu | Deputy GM & Director | — | male |
| Yuan Zhang | Deputy General Manager | — | female |
| Zhen Li | Financial Director, Secretary, Director & Deputy GM | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 301015.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
